Overview
Glycogen storage disease due to liver phosphorylase kinase deficiency (also known as GSD type IX, or PhK deficiency of the liver) is a group of inherited metabolic disorders in which the enzyme phosphorylase kinase is deficient or dysfunctional in the liver. Phosphorylase kinase plays a critical role in glycogen breakdown (glycogenolysis) by activating glycogen phosphorylase. When this enzyme is deficient, glycogen accumulates abnormally in the liver, leading to hepatomegaly (enlarged liver), growth retardation, and elevated liver transaminases. Affected children typically present in early childhood with a protuberant abdomen due to hepatomegaly, short stature, fasting hypoglycemia, and hyperlipidemia. Fasting ketosis may also occur. The condition is generally considered one of the milder glycogen storage diseases, and symptoms often improve with age, with many patients experiencing resolution of hepatomegaly and normalization of growth by adulthood. The most common form of liver phosphorylase kinase deficiency is X-linked (GSD IXa), caused by mutations in the PHKA2 gene, which encodes the liver-specific alpha subunit of phosphorylase kinase. Less common autosomal recessive forms exist, caused by mutations in the PHKB gene (encoding the beta subunit, GSD IXb) or the PHKG2 gene (encoding the liver-specific gamma subunit, GSD IXc). The PHKG2-related form tends to be more severe and may progress to liver fibrosis or cirrhosis in some cases. Diagnosis is based on clinical findings, biochemical testing (including enzyme activity assays in liver tissue or blood cells), and molecular genetic testing. Treatment is primarily supportive and dietary. Frequent meals rich in complex carbohydrates, avoidance of prolonged fasting, and in some cases cornstarch supplementation are used to maintain blood glucose levels and support normal growth. Protein supplementation may also be beneficial. Prognosis is generally favorable, particularly for the X-linked form, with most patients leading normal lives in adulthood. Regular monitoring of liver function and growth is recommended throughout childhood.
Also known as:
Clinical phenotype terms— hover any for plain English:
Variable
Can be inherited in different ways depending on the underlying gene
Childhood
Begins in childhood, roughly ages 1 to 12
Treatments
No FDA-approved treatments are currently listed for Glycogen storage disease due to liver phosphorylase kinase deficiency.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Glycogen storage disease due to liver phosphorylase kinase deficiency at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Glycogen storage disease due to liver phosphorylase kinase deficiency.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Glycogen storage disease due to liver phosphorylase kinase deficiency.
Community
No community posts yet. Be the first to share your experience with Glycogen storage disease due to liver phosphorylase kinase deficiency.
Start the conversation →Latest news about Glycogen storage disease due to liver phosphorylase kinase deficiency
No recent news articles for Glycogen storage disease due to liver phosphorylase kinase deficiency.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Glycogen storage disease due to liver phosphorylase kinase deficiency
What is Glycogen storage disease due to liver phosphorylase kinase deficiency?
Glycogen storage disease due to liver phosphorylase kinase deficiency (also known as GSD type IX, or PhK deficiency of the liver) is a group of inherited metabolic disorders in which the enzyme phosphorylase kinase is deficient or dysfunctional in the liver. Phosphorylase kinase plays a critical role in glycogen breakdown (glycogenolysis) by activating glycogen phosphorylase. When this enzyme is deficient, glycogen accumulates abnormally in the liver, leading to hepatomegaly (enlarged liver), growth retardation, and elevated liver transaminases. Affected children typically present in early chi
At what age does Glycogen storage disease due to liver phosphorylase kinase deficiency typically begin?
Typical onset of Glycogen storage disease due to liver phosphorylase kinase deficiency is childhood. Age of onset can vary across affected individuals.